PMA supplement
P130021 S155: Evolut FX+ TAV, Evolut FX DCS, Evolut FX LS
FDA PMA supplement · Normal 180 Day Track · Medtronic, Inc.
Key facts
| Original PMA | P130021 |
|---|---|
| Supplement number | S155 |
| Supplement type | Normal 180 Day Track |
| Reason for the supplement | Change Design/Components/Specifications/Material |
| Trade name | Evolut FX+ TAV, Evolut FX DCS, Evolut FX LS |
| Generic name | Aortic valve, prosthesis, percutaneously delivered |
| Applicant | Medtronic, Inc. |
| Product code | NPT |
| Received date | Jan 26, 2024 |
| Decision date | Mar 22, 2024 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: